Advanced search
Publication Cover
Journal of the American Statistical Association Volume 104, 2009 - Issue 487
Submit an article Journal homepage
822
Views
128
CrossRef citations to date
0
Altmetric
Applications and Case Studies

Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials

Guosheng Yin Guosheng Yin is Associate Professor and Ying Yuan is Assistant Professor, Department of Biostatistics, M. D. Anderson Cancer Center, University of Texas, Houston, TX 77230. The authors thank the editor, the associate editor, and two anonymous referees for their insightful and constructive comments that substantially improved the article.
&
Ying Yuan Guosheng Yin is Associate Professor and Ying Yuan is Assistant Professor, Department of Biostatistics, M. D. Anderson Cancer Center, University of Texas, Houston, TX 77230. The authors thank the editor, the associate editor, and two anonymous referees for their insightful and constructive comments that substantially improved the article.
Pages 954-968 | Received 01 Aug 2008, Published online: 01 Jan 2012

Citations (128)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (16)

Ziqing Wang, Jingyi Zhang, Tian Xia, Ruyue He & Fangrong Yan. (2023) A Bayesian phase I–II clinical trial design to find the biological optimal dose on drug combination. Journal of Biopharmaceutical Statistics 0:0, pages 1-14.
Read now
Koichi Hashizume, Jun Tsuchida & Takashi Sozu. (2023) Copula-Based Model for Incorporating Single-Agent Historical Data into Dual-Agent Phase I Cancer Trials. Statistics in Biopharmaceutical Research 0:0, pages 1-18.
Read now
Weijia Zhang, Xikui Wang, Saman Muthukumarana & Po Yang. (2023) A continual reassessment method without undue risk of toxicity. Communications in Statistics - Simulation and Computation 52:4, pages 1179-1191.
Read now
Xin Chen, Jingyi Zhang, Qian Jiang & Fangrong Yan. (2022) Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors. Journal of Biopharmaceutical Statistics 32:1, pages 34-52.
Read now
Weijia Zhang, Xikui Wang & Po Yang. (2021) A new design of the continual reassessment method. Communications in Statistics - Simulation and Computation 50:7, pages 2015-2024.
Read now
Yanhong Zhou, Ruobing Li, Fangrong Yan, J. Jack Lee & Ying Yuan. (2021) A Comparative Study of Bayesian Optimal Interval (BOIN) Design With Interval 3 + 3 (i3 + 3) Design for Phase I Oncology Dose-Finding Trials. Statistics in Biopharmaceutical Research 13:2, pages 147-155.
Read now
Jun Yin & Ying Yuan. (2020) Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials. Journal of Biopharmaceutical Statistics 30:6, pages 1006-1025.
Read now
Efehan Ulas, Filiz Karaman & Tuba Koc. (2020) Impact of different model structure and prior distribution in continual reassessment method. Communications in Statistics - Simulation and Computation 49:1, pages 95-109.
Read now
François Curtin & Stephane Heritier. (2017) The role of adaptive trial designs in drug development. Expert Review of Clinical Pharmacology 10:7, pages 727-736.
Read now
Bo Huang, Paul Bycott & Enayet Talukder. (2017) Novel dose-finding designs and considerations on practical implementations in oncology clinical trials. Journal of Biopharmaceutical Statistics 27:1, pages 44-55.
Read now
Alexia Iasonos & John O’Quigley. (2016) Dose Expansion Cohorts in Phase I Trials. Statistics in Biopharmaceutical Research 8:2, pages 161-170.
Read now
Takashi Asakawa, Akihiro Hirakawa & Chikuma Hamada. (2014) Bayesian Model Averaging Continual Reassessment Method for Bivariate Binary Efficacy and Toxicity Outcomes in Phase I Oncology Trials. Journal of Biopharmaceutical Statistics 24:2, pages 310-325.
Read now
Christopher C. Drovandi, James M. McGree,Anthony N. Pettitt. (2014) A Sequential Monte Carlo Algorithm to Incorporate Model Uncertainty in Bayesian Sequential Design. Journal of Computational and Graphical Statistics 23:1, pages 3-24.
Read now
Jin Zhang & ThomasM. Braun. (2013) A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients. Journal of the American Statistical Association 108:503, pages 892-901.
Read now
Guosheng Yin, Shurong Zheng & Jiajing Xu. (2013) Fractional Dose-Finding Methods with Late-Onset Toxicity in Phase I Clinical Trials. Journal of Biopharmaceutical Statistics 23:4, pages 856-870.
Read now
Ying Yuan & Guosheng Yin. (2011) Robust EM Continual Reassessment Method in Oncology Dose Finding. Journal of the American Statistical Association 106:495, pages 818-831.
Read now

Articles from other publishers (112)

Jingyi Zhang, Fangrong Yan, Nolan A Wages & Ruitao Lin. (2023) Local continual reassessment methods for dose finding and optimization in drug-combination trials. Statistical Methods in Medical Research.
Crossref
Jingyi Zhang, Xin Chen, Bosheng Li & Fangrong Yan. (2023) A comparative study of adaptive trial designs for dose optimization. Pharmaceutical Statistics.
Crossref
Huaqing Jin & Guosheng Yin. (2023) Time‐to‐event calibration‐free odds design: A robust efficient design for phase I trials with late‐onset outcomes. Pharmaceutical Statistics.
Crossref
Yingjie Qiu, Yi Zhao, Hao Liu, Sha Cao, Chi Zhang & Yong Zang. (2023) Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose. Contemporary Clinical Trials 127, pages 107139.
Crossref
Weijia Zhang, Wanni Lei & Xiaojun Zhu. (2023) A novel model of the continual reassessment method in Phase I trial. Scientific Reports 13:1.
Crossref
Chenyu Lin, Rachel A. DiCioccio, Tarek Haykal, William C. McManigle, Zhiguo Li, Sarah M. Anand, Jonathan C. Poe, Sonali J. Bracken, Wei Jia, Edwin P. AlyeaIIIIII, Adela R. Cardones, Taewoong Choi, Cristina Gasparetto, Michael R. Grunwald, Therese Hennig, Yubin Kang, Gwynn D. Long, Richard Lopez, Melissa Martin, Kerry K. Minor, Victor L. Perez Quinones, Anthony D. Sung, Kristi Wiggins, Nelson J. Chao, Mitchell E. Horwitz, David A. Rizzieri & Stefanie Sarantopoulos. (2023) A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease. Transplantation and Cellular Therapy 29:3, pages 179.e1-179.e10.
Crossref
Yanhong Zhou, Yujie Zhao, Greg Cicconetti, Yunming Mu, Ying Yuan, Li Wang, Sudhir Penugonda & Zeena Salman. (2022) AIDE : Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials . Pharmaceutical Statistics 22:2, pages 300-311.
Crossref
Nathaniel S. O'Connell, Nolan A. Wages & Elizabeth Garrett-Mayer. (2023) Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials. Contemporary Clinical Trials 125, pages 107050.
Crossref
Yubin Kang, Pasupathi Sundaramoorthy, Cristina Gasparetto, Daniel Feinberg, Shengjun Fan, Gwynn Long, Emily Sellars, Anderson Garrett, Sascha A. Tuchman, Brandi N. Reeves, Zhiguo Li, Bei Liu, Besim Ogretmen, Lynn Maines, Vered Katz Ben-Yair, Charles Smith & Terry Plasse. (2022) Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma. Annals of Hematology 102:2, pages 369-383.
Crossref
Haitao Pan & Ying YuanHaitao Pan & Ying Yuan. 2023. Bayesian Adaptive Design for Immunotherapy and Targeted Therapy. Bayesian Adaptive Design for Immunotherapy and Targeted Therapy 149 200 .
Haitao Pan & Ying YuanHaitao Pan & Ying Yuan. 2023. Bayesian Adaptive Design for Immunotherapy and Targeted Therapy. Bayesian Adaptive Design for Immunotherapy and Targeted Therapy 3 14 .
Wenbin Du, Huaqing JinChao Yu & Guosheng Yin. (2022) Deep Reinforcement Learning for Bandit Arm Localization. Deep Reinforcement Learning for Bandit Arm Localization.
Huaqing Jin, Wenbin Du & Guosheng Yin. (2022) Approximate Bayesian computation design for phase I clinical trials. Statistical Methods in Medical Research 31:12, pages 2310-2322.
Crossref
Ying Yuan & Yixuan Zhao. (2022) Commentary on “Improving the performance of Bayesian logistic regression model with overdose control in oncology dose‐finding studies”. Statistics in Medicine 41:27, pages 5484-5490.
Crossref
Tomoyoshi Hatayama & Seiichi Yasui. (2022) CUSUMIN : A cumulative sum interval design for cancer phase I dose finding studies . Pharmaceutical Statistics 21:6, pages 1324-1341.
Crossref
J. Jack Lee & Donald A. Berry. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine 1 15 .
Matthieu Clertant. (2022) Early-Phase Oncology Trials: Why So Many Designs?. Journal of Clinical Oncology.
Crossref
Haitao Pan, Rongji Mu, Chia-Wei Hsu & Shouhao Zhou. (2022) An R package UnifiedDoseFinding for continuous and ordinal outcomes in Phase I dose-finding trials . Communications for Statistical Applications and Methods 29:4, pages 421-439.
Crossref
Koichi Hashizume, Kentaro TakedaHiroyuki Sato, Akihiro Hirakawa & Takashi Sozu. (2022) Overview of model-assisted design for phase I dose-finding trials in oncologyがん第1相用量探索試験におけるモデル支援型デザインの最近の展開. Japanese Journal of Biometrics 43:1, pages 3-36.
Crossref
Rio AkazawaKentaro TakedaSatoshi Morita & Koichi Uegaki. (2022) An example of planning, conducting, and decision making in an oncology dose-finding trial with expansion cohorts拡大コホートを伴う抗がん剤用量探索試験の計画、実装、意思決定の実例. Japanese Journal of Biometrics 42:2, pages 65-81.
Crossref
Yanhong Zhou, Ruitao Lin, Ying-Wei Kuo, J. Jack Lee & Ying Yuan. (2021) BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. JCO Clinical Cancer Informatics:5, pages 91-101.
Crossref
G. D. James, S. Symeonides, J. Marshall, J. Young & G. Clack. (2021) Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies. BMC Cancer 21:1.
Crossref
Rongji Mu, Zongliang Hu, Guoying Xu & Haitao Pan. (2021) An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials. BMC Medical Research Methodology 21:1.
Crossref
Burak Kürsad Günhan, Sebastian Weber, Abdelkader Seroutou & Tim Friede. (2021) Phase I dose-escalation oncology trials with sequential multiple schedules. BMC Medical Research Methodology 21:1.
Crossref
Yanhong Zhou, J. Jack Lee, Shunguang Wang, Stuart Bailey & Ying Yuan. (2021) Incorporating historical information to improve phase I clinical trials. Pharmaceutical Statistics 20:6, pages 1017-1034.
Crossref
Jose Carlos Benitez, Arthur Geraud, Matthieu Texier, Christophe Massard, Angelo Paci, Jean-Charles Soria & Benjamin Besse. (2021) Late phase 1 studies: concepts and outcomes. The Lancet Oncology 22:10, pages e446-e455.
Crossref
Steven B. Kim, Dong Sub Kim & Christina Magana-Ramirez. (2021) Applications of statistical experimental designs to improve statistical inference in weed management. PLOS ONE 16:9, pages e0257472.
Crossref
Liyun Jiang, Lei Nie, Fangrong Yan & Ying Yuan. (2021) Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials. Contemporary Clinical Trials 107, pages 106460.
Crossref
Thomas A. Murray. (2021) Logistic retainment interval dose exploration design for Phase I clinical trials of cytotoxic agents. Pharmaceutical Statistics 20:4, pages 850-863.
Crossref
Masahiro Kojima. (2021) Early completion of phase I cancer clinical trials with Bayesian optimal interval design. Statistics in Medicine 40:14, pages 3215-3226.
Crossref
Haiyan Zheng, Lisa V Hampson & Thomas Jaki. (2021) Bridging across patient subgroups in phase I oncology trials that incorporate animal data. Statistical Methods in Medical Research 30:4, pages 1057-1071.
Crossref
Ami Takahashi & Taiji Suzuki. (2021) Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials. Contemporary Clinical Trials Communications 21, pages 100753.
Crossref
Minjeong Park, Suyu Liu, Timothy Anthony Yap & Ying Yuan. (2021) Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials. JAMA Network Open 4:2, pages e2037563.
Crossref
Steven Kim & Christopher Essert. (2021) A STATISTICAL APPROACH FOR RELIABLE MEASUREMENT WITH FAMILIARIZATION TRIALS. Sport Scientific And Practical Aspects: International Scientific Journal of Kinesiology 18:2, pages 5-11.
Crossref
Thomas M. Braun. (2020) A simulation‐free approach to assessing the performance of the continual reassessment method. Statistics in Medicine 39:30, pages 4651-4666.
Crossref
D. Dinart, J. Fraisse, D. Tosi, A. Mauguen, C. Touraine, S. Gourgou, M. C. Le Deley, C. Bellera & C. Mollevi. (2020) GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials. BMC Medical Informatics and Decision Making 20:1.
Crossref
Yimei Li & Ying Yuan. (2020) PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials. Biometrics 76:4, pages 1364-1373.
Crossref
Adrien Ollier, Satoshi Morita, Moreno Ursino & Sarah Zohar. (2019) An adaptive power prior for sequential clinical trials – Application to bridging studies. Statistical Methods in Medical Research 29:8, pages 2282-2294.
Crossref
Nolan A. Wages & Craig L. SlingluffJr.Jr.. (2019) Flexible Phase I–II Design for Partially Ordered Regimens with Application to Therapeutic Cancer Vaccines. Statistics in Biosciences 12:2, pages 104-123.
Crossref
Haitao Pan, Ruitao Lin, Yanhong Zhou & Ying Yuan. (2020) Keyboard design for phase I drug-combination trials. Contemporary Clinical Trials 92, pages 105972.
Crossref
Ruitao Lin, Peter F. Thall & Ying Yuan. (2019) An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes. Biometrics 76:1, pages 304-315.
Crossref
Lauren E. Colbert, Ying Yuan, Jaap D. Zindler, Clifton D. Fuller & Charles R. Thomas. 2020. Phase I Oncology Drug Development. Phase I Oncology Drug Development 283 296 .
Ruitao Lin & J. Jack Lee. 2020. Computational and Methodological Statistics and Biostatistics. Computational and Methodological Statistics and Biostatistics 395 426 .
Ying Yuan, J. Jack Lee & Susan G. Hilsenbeck. (2019) Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. JCO Precision Oncology:3, pages 1-12.
Crossref
Keren Naa Abeka Arthur & Alex Yaw Adom. (2019) Explorative study of entrepreneurship training programmes in Christian institutions in Ghana. Journal of Enterprising Communities: People and Places in the Global Economy 14:5, pages 713-727.
Crossref
Lai Wei, Xueliang Pan & Soledad Fernandez. (2019) Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials. Future Drug Discovery 1:2.
Crossref
Yaqian Zhu, Wei-Ting Hwang & Yimei Li. (2019) Evaluating the effects of design parameters on the performances of phase I trial designs. Contemporary Clinical Trials Communications 15, pages 100379.
Crossref
Rui Tang, Jing Shen & Ying Yuan. (2018) ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage. Statistics in Medicine 38:7, pages 1120-1134.
Crossref
Chenguang Wang, Gary L. Rosner & Richard B.S. Roden. (2018) A Bayesian design for phase I cancer therapeutic vaccine trials. Statistics in Medicine 38:7, pages 1170-1189.
Crossref
Bethany Jablonski Horton, Nolan A Wages & Mark R Conaway. (2018) Shift models for dose-finding in partially ordered groups. Clinical Trials 16:1, pages 32-40.
Crossref
Yimei Li, Ming Wang & Ying Kuen Cheung. (2018) Treatment and dose prioritization in early phase platform trials of targeted cancer therapies. Journal of the Royal Statistical Society: Series C (Applied Statistics) 68:2, pages 475-491.
Crossref
Rongji Mu, Ying Yuan, Jin Xu, Sumithra J. Mandrekar & Jun Yin. (2019) gBOIN: A Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points. Journal of the Royal Statistical Society Series C: Applied Statistics 68:2, pages 289-308.
Crossref
Takashi Daimon, Akihiro Hirakawa & Shigeyuki MatsuiTakashi Daimon, Akihiro Hirakawa & Shigeyuki Matsui. 2019. Dose-Finding Designs for Early-Phase Cancer Clinical Trials. Dose-Finding Designs for Early-Phase Cancer Clinical Trials 33 79 .
Niansheng Tang, Songjian Wang & Gen Ye. (2018) A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies. BMC Medical Research Methodology 18:1.
Crossref
Kristen M Cunanan & Joseph S Koopmeiners. (2017) Hierarchical models for sharing information across populations in phase I dose-escalation studies. Statistical Methods in Medical Research 27:11, pages 3447-3459.
Crossref
Heng Zhou, Ying Yuan & Lei Nie. (2018) Accuracy, Safety, and Reliability of Novel Phase I Trial Designs. Clinical Cancer Research 24:18, pages 4357-4364.
Crossref
Thomas M. Braun. (2018) Motivating sample sizes in adaptive Phase I trials via Bayesian posterior credible intervals. Biometrics 74:3, pages 1065-1071.
Crossref
Kentaro Takeda & Satoshi Morita. (2018) Bayesian dose‐finding phase I trial design incorporating historical data from a preceding trial. Pharmaceutical Statistics 17:4, pages 372-382.
Crossref
Heng Zhou, Thomas A. Murray, Haitao Pan & Ying Yuan. (2018) Comparative review of novel model-assisted designs for phase I clinical trials. Statistics in Medicine 37:14, pages 2208-2222.
Crossref
Caroline Petit, Adeline Samson, Satoshi Morita, Moreno Ursino, Jérémie Guedj, Vincent Jullien, Emmanuelle Comets & Sarah Zohar. (2016) Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies. Statistical Methods in Medical Research 27:6, pages 1860-1877.
Crossref
Tiago M. Fragoso, Wesley Bertoli & Francisco Louzada. (2018) Bayesian Model Averaging: A Systematic Review and Conceptual Classification. International Statistical Review 86:1, pages 1-28.
Crossref
Ying Yuan, Heng Zhou & Yanhong Zhou. 2018. Biopharmaceutical Applied Statistics Symposium. Biopharmaceutical Applied Statistics Symposium 205 233 .
David FletcherDavid Fletcher. 2018. Model Averaging. Model Averaging 1 29 .
Chunyan Cai, Mohammad H. Rahbar, Md Monir Hossain, Ying Yuan & Nicole R. Gonzales. (2017) A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research. Contemporary Clinical Trials Communications 7, pages 11-17.
Crossref
Lorenzo Capretto, Gerard Byrne, Sarah Trenfield, Lee Dowden & Steven Booth. 2017. Oral Formulation Roadmap from Early Drug Discovery to Development. Oral Formulation Roadmap from Early Drug Discovery to Development 165 241 .
J. Jack Lee & Donald A. Berry. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine 1 18 .
Haitao Pan & Ying Yuan. (2016) A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Statistics in Medicine 36:2, pages 266-279.
Crossref
Yong ZangJ. Jack Lee. (2017) A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials. Statistics in Medicine 36:1, pages 27-42.
Crossref
Ruitao Lin & Guosheng Yin. (2016) Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials. The Annals of Applied Statistics 10:4.
Crossref
Gareth D. James, Stefan N. Symeonides, Jayne Marshall, Julia Young & Glen Clack. (2016) Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data. BMC Cancer 16:1.
Crossref
Alexia Iasonos & John O'Quigley. (2016) Integrating the escalation and dose expansion studies into a unified Phase I clinical trial. Contemporary Clinical Trials 50, pages 124-134.
Crossref
Jiajing Xu, Guosheng Yin, David Ohlssen & Frank Bretz. (2016) Bayesian Two-Stage Dose Finding for Cytostatic Agents Via Model Adaptation. Journal of the Royal Statistical Society Series C: Applied Statistics 65:3, pages 465-482.
Crossref
Ruitao Lin & Guosheng Yin. 2016. Advanced Statistical Methods in Data Science. Advanced Statistical Methods in Data Science 55 74 .
Wentian Guo, Yang Ni & Yuan Ji. (2015) TEAMS: Toxicity- and Efficacy-Based Dose-Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology. Statistics in Biosciences 7:2, pages 432-459.
Crossref
Suyu LiuHaitao Pan, Jielai Xia, Qin Huang & Ying Yuan. (2015) Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Statistics in Medicine 34:10, pages 1681-1694.
Crossref
Jeffrey S. WeberLaura A. LevitPeter C. AdamsonSuanna BruinoogeHoward A. BurrisMichael A. CarducciAdam P. DickerMithat GönenStephen M. KeefeMichael A. PostowMichael A. ThompsonDavid M. WaterhouseSusan L. WeinerLynn M. Schuchter. (2015) American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology 33:3, pages 278-284.
Crossref
Jay BartroffTze Leung LaiBalasubramanian Narasimhan. (2014) A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies. Statistics in Medicine 33:16, pages 2718-2735.
Crossref
Haitao Pan, Cailin Zhu, Feng Zhang, Ying Yuan, Shemin Zhang, Wenhong Zhang, Chanjuan Li, Ling Wang & Jielai Xia. (2014) The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Model Selection Approach. PLoS ONE 9:5, pages e98147.
Crossref
J. Jack Lee & Caleb T. Chu. 2014. Lung Cancer. Lung Cancer 488 504 .
Oleksandr Sverdlov, Weng Kee Wong & Yevgen Ryeznik. (2014) Adaptive clinical trial designs for phase I cancer studies. Statistics Surveys 8:none.
Crossref
James X. Song. (2014) A two-stage patient enrichment adaptive design in phase II oncology trials. Contemporary Clinical Trials 37:1, pages 148-154.
Crossref
L. PozziH. Schmidli, M. Gasparini & A. Racine-Poon. (2013) A Bayesian adaptive dose selection procedure with an overdispersed count endpoint. Statistics in Medicine 32:28, pages 5008-5027.
Crossref
Suyu Liu, Guosheng Yin & Ying Yuan. (2013) Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. The Annals of Applied Statistics 7:4.
Crossref
Takashi Daimon & Sarah Zohar. (2013) An adaptive model switching approach for phase I dose-finding trials. Pharmaceutical Statistics 12:4, pages 225-232.
Crossref
Jin ZhangThomas M. BraunJeremy M.G. Taylor. (2012) Adaptive prior variance calibration in the Bayesian continual reassessment method. Statistics in Medicine 32:13, pages 2221-2234.
Crossref
Sarah Zohar, Matthieu Resche-Rigon & Sylvie Chevret. (2011) Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. Clinical Trials 10:3, pages 414-421.
Crossref
Nelson Kinnersley & Simon Day. (2013) Structured approach to the elicitation of expert beliefs for a Bayesian-designed clinical trial: a case study. Pharmaceutical Statistics 12:2, pages 104-113.
Crossref
Bradley P Carlin, Wei Zhong & Joseph S Koopmeiners. (2013) Discussion of ‘Small-sample behavior of novel phase I cancer trial designs’ by Assaf P Oron and Peter D Hoff. Clinical Trials 10:1, pages 81-85.
Crossref
Assaf P Oron & Peter D Hoff. (2013) Small-sample behavior of novel phase I cancer trial designs. Clinical Trials 10:1, pages 63-80.
Crossref
Jay Bartroff, Tze Leung Lai & Mei-Chiung ShihJay Bartroff, Tze Leung Lai & Mei-Chiung Shih. 2013. Sequential Experimentation in Clinical Trials. Sequential Experimentation in Clinical Trials 187 223 .
Jay Bartroff, Tze Leung Lai & Mei-Chiung ShihJay Bartroff, Tze Leung Lai & Mei-Chiung Shih. 2013. Sequential Experimentation in Clinical Trials. Sequential Experimentation in Clinical Trials 153 186 .
Jay Bartroff, Tze Leung Lai & Mei-Chiung ShihJay Bartroff, Tze Leung Lai & Mei-Chiung Shih. 2013. Sequential Experimentation in Clinical Trials. Sequential Experimentation in Clinical Trials 123 152 .
Jay Bartroff, Tze Leung Lai & Mei-Chiung ShihJay Bartroff, Tze Leung Lai & Mei-Chiung Shih. 2013. Sequential Experimentation in Clinical Trials. Sequential Experimentation in Clinical Trials 101 122 .
Jay Bartroff, Tze Leung Lai & Mei-Chiung ShihJay Bartroff, Tze Leung Lai & Mei-Chiung Shih. 2013. Sequential Experimentation in Clinical Trials. Sequential Experimentation in Clinical Trials 77 100 .
Jay Bartroff, Tze Leung Lai & Mei-Chiung ShihJay Bartroff, Tze Leung Lai & Mei-Chiung Shih. 2013. Sequential Experimentation in Clinical Trials. Sequential Experimentation in Clinical Trials 37 75 .
Jay Bartroff, Tze Leung Lai & Mei-Chiung ShihJay Bartroff, Tze Leung Lai & Mei-Chiung Shih. 2013. Sequential Experimentation in Clinical Trials. Sequential Experimentation in Clinical Trials 11 35 .
Jay Bartroff, Tze Leung Lai & Mei-Chiung ShihJay Bartroff, Tze Leung Lai & Mei-Chiung Shih. 2013. Sequential Experimentation in Clinical Trials. Sequential Experimentation in Clinical Trials 1 10 .
Alexia IasonosJohn O'Quigley. (2012) Interplay of priors and skeletons in two‐stage continual reassessment method. Statistics in Medicine 31:30, pages 4321-4336.
Crossref
Lin Huo, Ying Yuan & Guosheng Yin. (2012) Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses. Bayesian Analysis 7:4.
Crossref
John Crowley & Antje HoeringJohn O’Quigley & Alexia Iasonos. 2012. Handbook of Statistics in Clinical Oncology, Third Edition. Handbook of Statistics in Clinical Oncology, Third Edition 21 52 .
John Crowley & Antje HoeringJ Lee & Nan Chen. 2012. Handbook of Statistics in Clinical Oncology, Third Edition. Handbook of Statistics in Clinical Oncology, Third Edition 305 324 .
Takashi Daimon. (2012) The Continual Reassessment Method (CRM) and Related Topics^|^mdash;A Review. Part II: Modified/Extended CRMs and Related Designs.. Japanese Journal of Biometrics 33:1, pages 31-76.
Crossref
Takashi ASAKAWA, Naoki ISHIZUKA & Chikuma HAMADA. (2012) A Continual Reassessment Method that Adaptively Changes the Prior Distribution According to the Initial Cohort Observation. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 43:1, pages 21-28.
Crossref
Guosheng Yin. 2011. Clinical Trial Design. Clinical Trial Design 311 327 .
Alexia Iasonos & John O'Quigley. (2011) Continual reassessment and related designs in dose‐finding studies. Statistics in Medicine 30:17, pages 2057-2061.
Crossref
Ying Yuan & Guosheng Yin. (2011) Bayesian hybrid dose‐finding design in phase I oncology clinical trials. Statistics in Medicine 30:17, pages 2098-2108.
Crossref
Shing M. Lee & Ying Kuen Cheung. (2011) Calibration of prior variance in the Bayesian continual reassessment method. Statistics in Medicine 30:17, pages 2081-2089.
Crossref
John O'Quigley & Mark Conaway. (2011) Extended model‐based designs for more complex dose‐finding studies. Statistics in Medicine 30:17, pages 2062-2069.
Crossref
T. Daimon, S. Zohar & J. O'Quigley. (2011) Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method. Statistics in Medicine 30:13, pages 1563-1573.
Crossref
Mark ChangMark Chang. 2011. Modern Issues and Methods in Biostatistics. Modern Issues and Methods in Biostatistics 261 289 .
Guosheng Yin & Ying Yuan. 2010. Handbook of Adaptive Designs in Pharmaceutical and Clinical Development. Handbook of Adaptive Designs in Pharmaceutical and Clinical Development 3-1 3-19 .
John O’Quigley & Mark Conaway. (2010) Continual Reassessment and Related Dose-Finding Designs. Statistical Science 25:2.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.